|Bid||5.35 x 1000|
|Ask||5.40 x 800|
|Day's Range||5.51 - 6.94|
|52 Week Range||4.27 - 14.87|
|Beta (5Y Monthly)||3.05|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Aravive shares jumped after the oncology-drug specialist reported progress in a trial of a drug to treat kidney cancer.
Aravive (ARAV) delivered earnings and revenue surprises of 2.22% and -54.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
This week we saw the Aravive, Inc. ( NASDAQ:ARAV ) share price climb by 16%. But that doesn't change the fact that the...